Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications.
Mycobacterium avium complex
clarithromycin
immunocompromised host
nontuberculous mycobacteria
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
11
08
2021
accepted:
19
11
2021
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
7
1
2022
Statut:
epublish
Résumé
Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events (10/13 vs 14/17;
Identifiants
pubmed: 34988253
doi: 10.1093/ofid/ofab582
pii: ofab582
pmc: PMC8709895
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab582Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
J Pharm Health Care Sci. 2015 Nov 14;1:32
pubmed: 26819743
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Clin Chest Med. 2015 Mar;36(1):35-41
pubmed: 25676517
J Thorac Dis. 2019 Sep;11(9):3814-3821
pubmed: 31656654
Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1766-72
pubmed: 8665032
Semin Respir Crit Care Med. 2013 Feb;34(1):135-42
pubmed: 23460013
Tuberc Respir Dis (Seoul). 2019 Jan;82(1):15-26
pubmed: 30574687
Eur Respir J. 2018 Mar 22;51(3):
pubmed: 29567726
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64
pubmed: 29054853
Am J Respir Crit Care Med. 2015 Sep 15;192(6):754-60
pubmed: 26068042
J Antimicrob Chemother. 2016 Jul;71(7):1759-71
pubmed: 27009031